10499 related articles for article (PubMed ID: 14660055)
1. Serum interleukin-6 concentrations as predictive factor of time to progression in metastatic malignant melanoma patients treated by biochemotherapy: a retrospective study.
Mouawad R; Rixe O; Meric JB; Khayat D; Soubrane C
Cytokines Cell Mol Ther; 2002; 7(4):151-6. PubMed ID: 14660055
[TBL] [Abstract][Full Text] [Related]
2. Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy.
Minor DR; Moore D; Kim C; Kashani-Sabet M; Venna SS; Wang W; Boasberg P; O'Day S
Oncologist; 2009 Oct; 14(10):995-1002. PubMed ID: 19776094
[TBL] [Abstract][Full Text] [Related]
3. Endogenous interleukin 6 levels in patients with metastatic malignant melanoma: correlation with tumor burden.
Mouawad R; Benhammouda A; Rixe O; Antoine EC; Borel C; Weil M; Khayat D; Soubrane C
Clin Cancer Res; 1996 Aug; 2(8):1405-9. PubMed ID: 9816314
[TBL] [Abstract][Full Text] [Related]
4. Serum interleukin-10 levels in patients with advanced gastrointestinal malignancies.
De Vita F; Orditura M; Galizia G; Romano C; Infusino S; Auriemma A; Lieto E; Catalano G
Cancer; 1999 Nov; 86(10):1936-43. PubMed ID: 10570416
[TBL] [Abstract][Full Text] [Related]
5. Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma.
Zhang GJ; Adachi I
Anticancer Res; 1999; 19(2B):1427-32. PubMed ID: 10365118
[TBL] [Abstract][Full Text] [Related]
6. An unexpected inverse correlation between soluble epidermal growth factor receptor and interleukin-6 in metastatic malignant melanoma patients.
Mouawad R; Soubrane C; Rixe O; Khayat D; Spano JP
Melanoma Res; 2006 Aug; 16(4):335-40. PubMed ID: 16845329
[TBL] [Abstract][Full Text] [Related]
7. Melanoma-inhibitory activity protein concentrations in blood of melanoma patients treated with immunotherapy.
Dréau D; Bosserhoff AK; White RL; Buettner R; Holder WD
Oncol Res; 1999; 11(1):55-61. PubMed ID: 10451031
[TBL] [Abstract][Full Text] [Related]
8. Single-institution outcome of high-dose interleukin-2 (HD IL-2) therapy for metastatic melanoma and analysis of favorable response in brain metastases.
Powell S; Dudek AZ
Anticancer Res; 2009 Oct; 29(10):4189-93. PubMed ID: 19846971
[TBL] [Abstract][Full Text] [Related]
9. High-dose interleukin-2 in patients with metastatic melanoma whose disease progressed after biochemotherapy.
Buzaid AC; Schmerling RA; Vieira Guedes RA; de Freitas D; William WN
Melanoma Res; 2011 Aug; 21(4):370-5. PubMed ID: 21558968
[TBL] [Abstract][Full Text] [Related]
10. Pretreatment serum interleukin-6 concentration as a prognostic factor of overall survival in metastatic malignant melanoma patients treated with biochemotherapy: a retrospective study.
Soubrane C; Rixe O; Meric JB; Khayat D; Mouawad R
Melanoma Res; 2005 Jun; 15(3):199-204. PubMed ID: 15917702
[TBL] [Abstract][Full Text] [Related]
11. Biochemotherapy in patients with advanced head and neck mucosal melanoma.
Bartell HL; Bedikian AY; Papadopoulos NE; Dett TK; Ballo MT; Myers JN; Hwu P; Kim KB
Head Neck; 2008 Dec; 30(12):1592-8. PubMed ID: 18798304
[TBL] [Abstract][Full Text] [Related]
12. Decreased IL-1 RA concentration in ascites is associated with a significant improvement in overall survival in ovarian cancer.
Mustea A; Pirvulescu C; Könsgen D; Braicu EI; Yuan S; Sun P; Lichtenegger W; Sehouli J
Cytokine; 2008 Apr; 42(1):77-84. PubMed ID: 18329282
[TBL] [Abstract][Full Text] [Related]
13. [Prognostic significance of DNA ploidy in disseminated malignant skin melanoma and the effectiveness of interleukin-2 (IL-2) treatment].
Novik AV; Novik BI; Moiseenko VM
Vopr Onkol; 2007; 53(2):164-9. PubMed ID: 17663169
[TBL] [Abstract][Full Text] [Related]
14. Impact of gene polymorphisms on clinical outcome for stage IV melanoma patients treated with biochemotherapy: an exploratory study.
Liu D; O'Day SJ; Yang D; Boasberg P; Milford R; Kristedja T; Groshen S; Weber J
Clin Cancer Res; 2005 Feb; 11(3):1237-46. PubMed ID: 15709194
[TBL] [Abstract][Full Text] [Related]
15. Does chemosensitivity-assay-directed therapy have an influence on the prognosis of patients with malignant melanoma stage IV? A retrospective study of 14 patients with malignant melanoma stage IV.
Doerler M; Hyun J; Venten I; Potthoff A; Bartke U; Serova K; Hoextermann S; Altmeyer P; Brockmeyer NH
Eur J Med Res; 2007 Oct; 12(10):497-502. PubMed ID: 18024256
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of serum 5-S-cysteinyldopa for monitoring human metastatic melanoma during immunochemotherapy.
Wimmer I; Meyer JC; Seifert B; Dummer R; Flace A; Burg G
Cancer Res; 1997 Nov; 57(22):5073-6. PubMed ID: 9371505
[TBL] [Abstract][Full Text] [Related]
17. Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial.
Schmidt H; Suciu S; Punt CJ; Gore M; Kruit W; Patel P; Lienard D; von der Maase H; Eggermont AM; Keilholz U; ;
J Clin Oncol; 2007 Apr; 25(12):1562-9. PubMed ID: 17443000
[TBL] [Abstract][Full Text] [Related]
18. Pilot study of high-dose, concurrent biochemotherapy for advanced melanoma.
Kim KB; Eton O; East MJ; Hodges C; Papadopoulos NE; Grimm EA; Bedikian AY
Cancer; 2004 Aug; 101(3):596-603. PubMed ID: 15274073
[TBL] [Abstract][Full Text] [Related]
19. Serum interleukin-8 level is a more sensitive marker than serum interleukin-6 level in monitoring the disease activity of recurrent aphthous ulcerations.
Sun A; Chang YF; Chia JS; Chiang CP
J Oral Pathol Med; 2004 Mar; 33(3):133-9. PubMed ID: 15128054
[TBL] [Abstract][Full Text] [Related]
20. High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma.
Nikkola J; Vihinen P; Vuoristo MS; Kellokumpu-Lehtinen P; Kähäri VM; Pyrhönen S
Clin Cancer Res; 2005 Jul; 11(14):5158-66. PubMed ID: 16033831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
